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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
medium-chain triglycerides and reduction in body weight (ID 643, 677, 
1614) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to medium-chain triglycerides and reduction in body weight. The scientific substantiation 
is based on the information provided by the Member States in the consolidated list of Article 13 
health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The food constituent that is the subject of the health claims is medium-chain triglycerides. In the 
context of the references provided, the Panel assumes that the food constituent which is the subject of 
the health claims is medium-chain fatty acids, which should replace long-chain fatty acids in 
triglycerides in order to obtain the claimed effect. The Panel considers that the food constituent, 
medium-chain fatty acids, which is the subject of the health claims, is sufficiently characterised in 
relation to the claimed effect. 
The claimed effect is “weight management”. The target population is assumed to be overweight 
individuals in the general population who wish to reduce their body weight. The Panel considers that 
reduction in body weight is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that the results from the human intervention 
studies provided are inconsistent with respect to the effects of medium-chain triglycerides on body 
weight loss, and that the evidence in support of a mechanism by which medium-chain triglycerides 
could exert the claimed effect is weak and not convincing. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1430, EFSA-Q-2008-1464, EFSA-Q-2008-2350, 
adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Weight Management/Satiety/Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette 
Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens. 
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The Panel concludes that a cause and effect relationship has not been established between the 
consumption of medium-chain triglycerides and reduction in body weight. 
KEY WORDS 
Medium-chain triglycerides, long-chain triglycerides, replacement, body weight, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claims is medium-chain triglycerides (MCTs). 
In the context of the references provided, the Panel assumes that the food constituent which is the 
subject of the health claims is medium-chain fatty acids (MCFAs), which should replace long-chain 
fatty acids (LCFAs) in triglycerides in order to obtain the claimed effect. In the context of the 
references provided, the Panel assumes that MCFAs (6-10 carbon atoms), mostly caprylic (C:8) and 
capric (C:10) acids in a ratio of approximately 2-3 to 1 in the form of triglycerides, should replace 
LCFAs (>12 carbon atoms) in the form of triglycerides (LCTs) in order to obtain the claimed effect.  
The Panel considers that the food constituent, MCTs, which is the subject of the health claims, is 
sufficiently characterised in relation to the claimed effect. 
2. Relevance of the claimed effect to human health (ID 643, 677, 1614) 
The claimed effect is “weight management”. The Panel assumes that the target population is 
overweight individuals in the general population who wish to reduce their body weight. 
In the context of the proposed wordings and the references provided, the Panel assumes that the 
claimed effect refers to reduction in body weight.  
Weight loss can be interpreted as the achievement of a normal body weight in previously overweight 
subjects. In this context, weight loss in overweight subjects without achieving a normal body weight 
is considered to be a beneficial physiological effect. 
The Panel considers that reduction in body weight is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect (ID 643, 677, 1614) 
The majority of the references provided for the scientific substantiation of the claim reported on the 
effects of food constituents other than MCTs and/or on health outcomes (e.g. acute or short-term 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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effects on appetite ratings, energy intake, fat oxidation and/or regulatory hormone concentrations, 
blood lipids, energy expenditure, and body composition) other than body weight. The Panel considers 
that no conclusions can be drawn from these references for the scientific substantiation of the claim.  
A total of ten publications reporting on nine human intervention studies which addressed the effects 
of MCT vs. LCT consumption on body weight were provided (Beermann et al., 2003; Han et al., 
2007; Kasai et al., 2003; Krotkiewski, 2001; Nosaka et al., 2003; St-Onge and Jones, 2003; St-Onge et 
al., 2003a; St-Onge et al., 2003b; Tsuji et al., 2001; Yost and Eckel, 1989). Two publications reported 
on the same study (St-Onge and Jones, 2003; St-Onge et al., 2003b).  
Two of the studies were designed to assess the metabolic effects of replacing LCTs by MCTs, and  
had a randomised, parallel design, a duration of two and four weeks, and included five and eight 
subjects per intervention group, respectively (Beermann et al., 2003; Yost and Eckel, 1989). The 
Panel notes the small sample size of these studies, which may have been inappropriate to assess 
changes in body weight, and considers that no conclusions can be drawn for the scientific 
substantiation of the claim. 
In a parallel, randomised, double-blind intervention study (Tsuji et al., 2001), the effects on body 
weight of 10 g/day MCTs were compared to the effects of 10g/day LCTs (blended rapeseed oil and 
soybean oil) in bread consumed daily at breakfast for 12 weeks in healthy men and women. A total of 
100 subjects were randomised but only 78 completed the study and entered data analysis. Dietary 
counselling was provided to all subjects at the beginning of the study. Compliance with the study diet 
aiming to maintain energy balance was self-reported. Body weight was measured at weeks 0, 4, 8 and 
12. Data from subjects with BMI 23 kg/m
2
 or <23 kg/m
2
 were presented separately. Data analyses 
for the entire study population were not provided. It is unclear whether this sub-group analysis was 
planned at recruitment [(BMI 23 kg/m
2
: n=26 (MCTs), n=30 (LCTs); BMI <23 kg/m
2
: n=15 
(MCTs), n=7 (LCTs)]. The differences in raw data were examined by two-way ANOVA. The 
significance of differences between the groups for the same period was assessed by unpaired 
Student’s t-test (two-tailed). It is unclear from the publication whether initial body weight was 
included as a covariate in the two-way ANOVA, or whether the MCT and LCT groups were 
comparable at baseline regarding body weight (mean SEM=75.7 1.9 kg vs. 72.8 1.1 kg). The Panel 
notes the substantial limitations of the study, and considers that no conclusions can be drawn from it 
for the scientific substantiation of the claim. 
In a randomised, cross-over, controlled feeding intervention (St-Onge et al., 2003a), the effects on 
body weight of diets rich in either MCTs or LCTs (as olive oil) for periods of four weeks each were 
assessed in 17 healthy obese women. Diets contained 40 % of energy as fat, 15 % as protein and 45 % 
as carbohydrates, were designed for body weight maintenance, and all meals were provided to the 
subjects for the duration of the study under strictly controlled conditions. Of the total amount of fat, 
75 % was derived from either beef tallow (LCTs) or a blend of saturated and unsaturated vegetable 
oils (MCTs). In the MCT diet, 50 % of the total fat was provided by MCT oil, rich in octanoate and 
decanoate (49 and 50 % of total fatty acids respectively), 10 % by olive oil and 5 % each by butter, 
coconut oil and flaxseed oil. An unesterified plant sterol/stanol mixture at a level of 22 mg/kg body 
weight/day was added to the MCT diet to maintain normal cholesterol concentrations. Wash-out 
periods were of 4-8 weeks to ensure that all women were assessed in the same phase of the menstrual 
cycle. No significant differences in weight loss between the two study phases were observed 
(-0.87 0.16 kg vs. -0.84 0.22 kg during MCT and LCT consumption, respectively). The Panel notes 
that this study did not show a significant effect of MCTs on body weight at doses of about 55 g/day 
for four weeks in the context of a diet aiming at energy balance. 
In a randomised, cross-over, controlled feeding trial (St-Onge and Jones, 2003; St-Onge et al., 2003b), 
the effects on body weight of diets rich in either MCTs or LCTs (as olive oil) for periods of four 
weeks each were assessed in 24 healthy overweight men. Diets contained 40 % of energy as fat, 15 % 
Medium-chain triglycerides and reduction in body weight 
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as protein and 45 % as carbohydrate, and were designed for body weight maintenance. The diets were 
identical except for the quality of the fat. The MCT-containing diet contained an oil composed of 
64.7 % MCT oil, 12.6 % olive oil, 6.8 % each of canola and flaxseed oil, and 5.8 % coconut oil as the 
main source of fat (75 % of total fat). The control diet (LCTs) contained 75 % of total fat as olive oil. 
The MCT oil also contained 3.4 % unesterified stanol/sterol mixture. No significant differences in 
weight loss between the two study phases were observed (-1.03 0.25 kg vs.-0.62 0.29 kg during 
MCT and LCT consumption, respectively). The Panel notes that this study did not show a significant 
effect of MCTs on body weight at doses of >55 g/day for four weeks in the context of a diet aiming at 
energy balance. 
In a parallel, randomised, double-blind intervention trial (Krotkiewski, 2001), the effects on body 
weight of MCT vs. LCT supplementation during a very low calorie diet (VLCD) were assessed. Three 
groups of matched obese women (BMI >30 kg/m
2
) received an isoenergetic (578.5 kcal) VLCD 
enriched with MCTs (8.0 g/100g providing 8 kcal/g, n=22) or LCTs (9.9 g/100 g providing 9 kcal/g, 
n=22), or a low-fat (3.0 g/100 g, n=22) and high-carbohydrate regimen. The diets were administered 
over four weeks. Body weight significantly decreased in the MCT group compared to the LCT and 
low-fat group at weeks 1 and 2 of the study, but no significant differences in body weight changes 
were observed between groups at the end of the study (weeks 3 and 4). The Panel notes that this 
short-term study did not show a significant effect of MCTs on body weight. 
In a parallel, randomised, double-blind intervention trial (Han et al., 2007), the effects on body weight 
of a test oil with MCTs (extracted from coconut oil, 100 % MCTs with a caprylic acid:capric acid 
ratio of 2:1) as compared to corn oil (control LCTs), at doses of 18 g/day administered as part of the 
daily diet were assessed in 40 free-living subjects with type-2 diabetes mellitus living in an urban area 
of China. Subjects were on treatment with oral antidiabetic medication (sulfonylureas, biguanides or 
α-glucosidase inhibitors), which were maintained constant during the study. All subjects completed 
the study and reported being fully compliant with the intervention. Body weight was assessed on days 
0, 45 and 90 of the study. Differences between groups at the same time point were assessed using 
ANOVA, with baseline data as covariate, and Tukey post-hoc tests. Body weight in the MCT group 
was significantly lower than in the LCT group at days 45 and 90 of the study (p<0.05; p=0.012 for the 
time-group interaction). Body weight decreased in the MCT group by approximately 1.5 kg, and 
increased by approximately 0.28 kg in the LCT group. The authors reported that no significant effect 
of medication use on body weight was detected in either group. However, the Panel notes that this 
effect was not formally tested in the study, and that the information provided is limited to the type of 
medication received by each study subject. A significant reduction in energy and fat intake assessed 
using a three-day weighed food record (first and last week of the study) was also observed in the 
MCT group compared to the LCT group. The Panel notes that a body weight difference of about -1.7 
kg in 12 weeks in favour of MCTs was observed in this study at doses of 18 g/day without imposed 
energy restriction. 
In a parallel, randomised, double-blind intervention trial (Nosaka et al., 2003), the effects on body 
weight of margarines (14 g/day) containing 5 g of MCTs or an equal amount of LCTs (blended 
rapeseed oil and soybean oil) consumed with bread at breakfast for 12 weeks were studied. Of the 
73 subjects (18 female) recruited and randomised, two dropped out for reasons unrelated to the study, 
and seven subjects were excluded from data analysis owing to protocol violation. Data analyses were 
conducted in the population of completers (n=64, n=33 in the MCT group) only. Dietary counselling 
was provided to all subjects at the beginning of the study. Compliance with the study diet aiming to 
maintain energy balance was self-reported. Body weight was measured at weeks 0, 4, 8 and 12. A 
significant reduction in body weight (p<0.05) was observed at week 12 in the MCT group as 
compared to the LCT group (mean SD=-4.2 2.8 kg vs.-2.9 2.0 kg) The Panel notes that a weight 
difference of about -1.3 kg in 12 weeks in favour of MCTs was observed at doses of 5 g/day in the 
context of an isoenergetic diet, and that differences in body weight between the MCT and LCT groups 
were only significant at week 12 of the study. 
Medium-chain triglycerides and reduction in body weight 
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In a parallel, randomised, double-blind intervention trial (Kasai et al., 2003), the effects on body 
weight of a test bread made with 14 g of cooking oil (obtained by transesterification of 14 % MCTs 
and 85 % rapeseed oil) with structured medium and long-chain triglycerides (MLCTs) containing 1.7 
g MCFAs were compared to the effects of a bread made with LCTs (blended rapeseed oil and soybean 
oil). Bread or control breads were consumed daily at breakfast for 12 weeks. Of the 93 subjects 
recruited and randomised, 10 could not consume the specified meal, and one subject dropped out. 
Data analyses were conducted in the population of completers (n=82, 7 female, n=40 in the MCT 
group, 4 female) only. Dietary counselling was provided to all subjects at the beginning of the study. 
Compliance with the study diet aiming to maintain energy balance was self-reported. Body weight 
was measured at weeks 0, 4, 8 and 12. A significant reduction in body weight (p<0.05) was observed 
at weeks 4, 8 and 12 in the MCT group as compared to the LCT group (mean SEM=-2.4 0.2 kg, -
3.5 0.3 kg, -4.5 0.4 kg in the MCT group at weeks 4, 8 and 12 as compared to -1.7 0.2 kg; -2.5 0.3 
kg; -3.3 0.4 kg in the LCT group). The Panel notes that a weight difference of about -1.2 kg in 12 
weeks in favour of MCTs was observed at doses of 1.7 g/day in the context of an isoenergetic diet, 
and that differences in body weight between the MCT and LCT groups were already significant at 4 
weeks (body weight loss difference of about -0.7 kg in favour of MCTs).  
The Panel notes that three human intervention studies of 12 week duration observed a significant 
effect of MCTs on body weight loss at MCT doses of 1.7-18 g/day in the context of diets aiming at 
energy balance (Han et al., 2007; Kasai et al., 2003; Nosaka et al., 2003), and that the body weight 
difference between the MCT and LCT groups (range 1.3-1.7 kg) was rather uniform and apparently 
independent of the MCT doses used. The Panel also notes that one of the studies already observed a 
significant effect of MCTs on body weight at four weeks (Kasai et al., 2003) using 1.7 g/day MCTs,  
whereas no effect of MCTs was reported at the same time point at higher doses (>50 g/day) in the 
context of isoenergetic (St-Onge and Jones, 2003; St-Onge et al., 2003a; St-Onge et al., 2003b) or 
energy-restricted (Krotkiewski, 2001) diets in more strictly controlled studies.  
A number of possible mechanisms by which MCTs could exert the claimed effect have been 
proposed, and the evidence for these has been reviewed by Kovacs and Mela (2006). MCTs are 
readily hydrolysed by lipases in the gastro-intestinal tract, and unlike LCTs are directly absorbed into 
the portal circulation and transported to the liver for oxidation. The intra-mitrochondrial transport of 
MCTs does not require carnitine palmitoyltransferase, which possibly accelerates oxidation of MCTs 
and possibly limits storage within tissues. However, the exact mechanism by which MCTs could have 
an effect on energy balance is unclear. In animals, there is some evidence that consumption of MCTs 
may increase satiety, decrease energy intake, and increase energy expenditure, resulting in lower body 
weight and smaller fat depots compared to isocaloric LCT consumption. However, results from 
human studies are conflicting. High intakes of MCTs lead to reduced energy intakes in some studies 
at doses of 18-60 g/day, but no effects on appetite, request for food or changes in any satiety-related 
hormone have been observed at these intake levels. Similarly, increased energy expenditure following 
consumption of MCTs at high doses (15-50 g/day) has been observed in the short-term (7 days), 
whereas results for longer periods of time are inconsistent. No effects of MCTs at lower doses of 
intake (about 10 g/day) have been observed on any of these variables. The Panel considers that the 
evidence provided for a mechanism by which MCTs could exert the claimed effect is weak and not 
convincing. 
In weighing the evidence, the Panel took into account that the results from the human intervention 
studies provided are inconsistent with respect to the effects of MCTs on body weight loss, and that the 
evidence in support of a mechanism by which MCTs could exert the claimed effect is weak and not 
convincing. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of MCTs and reduction in body weight. 
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CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent that is the subject of the health claims is medium-chain triglycerides 
(MCTs). It is assumed that the food constituent which is the subject of the health claims is 
medium-chain fatty acids (MCFAs), which should replace long-chain fatty acids (LCFAs) in 
triglycerides in order to obtain the claimed effect. The food constituent, MCTs, which is the 
subject of the health claims, is sufficiently characterised in relation to the claimed effect. 
 The claimed effect is “weight management”. The target population is assumed to be 
overweight individuals in the general population who wish to reduce their body weight. 
Reduction in body weight is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of MCTs 
and reduction in body weight. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1430, 
EFSA-Q-2008-1464, EFSA-Q-2008-2350). The scientific substantiation is based on the information 
provided by the Member States in the consolidated list of Article 13 health claims and references that 
EFSA has received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
Medium-chain triglycerides and reduction in body weight 
 
15 EFSA Journal 2011;9(6):2240 
APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to medium-chain triglycerides, including conditions of use 
from similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
643 medium chain triglycerides 
(MCT) 
weight management - helps to manage body weight, - 
helps to reduce body fat particularly 
in overweight persons, - helps to 
limit body fat accumulation, - helps 
to increase energy expenditure.  
Conditions of use 
- 5g/day 
- from 2g to 10g/day 
ID Food or Food constituent Health Relationship Proposed wording 
677 Medium Chain 
Triglycerides; MCT; 
Weight management Consumption of Medium Chain 
Triglycerides (MCT) inside the 
normal suggested fat consumption 
contributes to keep the healthy 
balanced body weight and helps to 
avoid fat deposition, with special 
regards to the abdominal fat.;;MCT 
helps to increase energy expenditure 
in comparison to the long chain 
fatty acides by increasing the 
metabolic rate. 
Conditions of use 
- 30-40 g/day short term use; 5 g/day;long term use 
ID Food or Food constituent Health Relationship Proposed wording 
1614 Medium Chain 
Triglycerides (MCT) 
Weight management Helps to increase satiety after a 
meal /helps to increase energy 
expenditure by increasing the 
metabolic rate /helps with weight 
loss by increasing metabolic rate 
/tends to reduce body weight and fat 
in overweight persons 
Conditions of use 
- 5g/day 
- 30-40 g/day short term use; 5 g/day;long term use 
- kurzfristig 30-40 g/Tag, langfristig 10 g/Tag  
- from 2g to 10g/day 
- 30-40 g/day short term use. 10 g/d long term use  
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GLOSSARY AND ABBREVIATIONS 
BMI  Body mass index 
LCFA  Long-chain fatty acid 
LCPUFA Long-chain polyunsaturated fatty acid 
LCSFA  Long-chain saturated fatty acid  
LCT  Long-chain triglyceride 
MCT  Medium-chain triglyceride 
MLCT  Medium and long-chain triglycerides 
VLCD  Very low calorie diet   
